Verona Pharma Plc (VRNA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Verona Pharma Plc (VRNA)
Go deeper and ask any question about VRNA
Company Performance
Current Price
as of Sep 13, 2024$29.78
P/E Ratio
N/A
Market Cap
$2.42B
Description
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Metrics
Overview
- HQLondon, GL
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerVRNA
- Price$29.78-0.70%
Trading Information
- Market Cap$2.42B
- Float77.44%
- Average Daily Volume (1m)1,082,291
- Average Daily Volume (3m)1,504,011
- EPS-$1.56
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$70.91M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$68.23M
- EV$985.59M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Earnings Calls